Skip to content

GlobeStar Therapeutics Corp

CIK 0001502152

← back to feed
Revenue (TTM)
$377
−81.9% YoY Q3 Oct 2024
Net Income (TTM)
−$1.82M
−31.0% YoY Q3 Oct 2024
EPS Diluted (TTM)
—
Q3 Oct 2024
Gross Margin
-618.8%
Q3 Oct 2024
Operating Margin
-476,417.5%
Q3 Oct 2024
Net Margin
-482,469.8%
Q3 Oct 2024
Free Cash Flow (TTM)
−$258.44K
Q3 Oct 2024
Cash
$41
Q3 Oct 2024
Total Debt
$59.65K
Q3 Oct 2024
Shares Outstanding
1.24B sh
Q3 Oct 2024

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings